Featured Product
This Week in Quality Digest Live
FDA Compliance Features
Jon Speer
As a medical device manufacturer, you can expect to be inspected
Dirk Dusharme @ Quality Digest
Huge amounts of biometric, DNA, and diagnostic data enable personalized medicine. They also enable unscrupulous and discriminatory marketing.
Nicole Radziwill
A cloud-based QMS can help address common international standards and regulations
Kelly Kuchinski
Particularly in regulated industries, you really do want to know what goes into the sausage
Mike Richman
A primer for life science manufacturers

More Features

FDA Compliance News
Creates adaptive system for managing product development and post-market quality for devices with software elements
VQIP allows for expedited review and importation for approved applicants that demonstrate safe supply chains
An invite from Alcon Laboratories
Intended to harmonize domestic and international requirements
The FDA wants medical device manufactures to succeed, new technologies in supply chain managment
Pharma quality teams will have performance-oriented objectives as well as regulatory compliance goals
Strategic investment positions EtQ to accelerate innovation efforts and growth strategy
The FDA’s RMAT designation goes live

More News

Patrick Stone

FDA Compliance

U.S. Drug Shortage Hits Patients, Pharmacies Hardest

Passively waiting for supply chain improvement isn’t the answer

Published: Thursday, September 3, 2015 - 16:29

The corner drug store isn’t currently affected by many drug shortages; instead, the pain is being inflicted on a vulnerable group of patients in hospitals today. The U.S. Food and Drug Administration (FDA) “officially” list the shortage of drug products as less than 200; however, the pharma warehouse industry pegs the list a bit higher at approximately 250 drug products.

This list includes drug container closure systems like sterile intravenous bags (IV). It’s important to include the component shortages because these also impede mitigation strategies in place at many of the nation’s hospital systems. Hospital compound pharmacies can formulate these admixtures even in short supply—but not without the IV bag components. The drug shortage list has fallen by almost half in the past three years but there is no quick fix here for underlying challenges.

For now, compound pharmacies may have to drastically expand and improve current facilities to fill sterile admixture demands. New supply chains for many generic drugs and IV drugs will have to go online with documented patient-safe compliant manufacturing systems.

The new drug inspectorate team investigators at FDA won’t be casual with their inspection approach, but neither will they be in a big rush to give a clean bill of health to the facilities under inspection. Quality by design inspection approaches over the quality systems model will globally standardize regulatory expectations.

Hospitals have adopted shortage mitigation plans that include stockpiling drugs on the shortage list and requesting that manufacturers extend the expiration dates through longer stability-indicating studies. The current inspection focus will be on sterile compound pharmacies and overseas generic manufacturers. The current focus on compound pharmacies will turn up many sterile compliance gaps and limited sterile benchtop space to meet these sterile drug-shortage mitigation plans. Hospitals may consider storing stockpiled drugs together and otherwise better networking with each other so that close expiration-dated stock is sent to hospitals with instant use demand.

Simply waiting passively for supply chain improvement will be a painful endeavor. The FDA may have to consider fostering domestic growth mitigation supply chain strategies for the pharma industry. The current focus will be for the FDA to bulk up international offices in the generic drug manufacturing sector of the world for increased supply.

Drugs on the shortage list include antibiotics, analgesics (CNS), cancer fighters (chemo), epinephrine, and IV drugs and total-nutrition IV components (TPN). Click here for the official current drug shortage list.

First published Aug. 17, 2015, on the AssurX blog.

Discuss

About The Author

Patrick Stone’s picture

Patrick Stone

Patrick Stone works toward a future where disease cures and prevention are the main goal of all new test articles. Stone is president and lead consultant at TradeStone QA LLC, which serves the global public by protecting the supply and quality of healthcare products before entering the market place. Stone specializes in Institutional Review Board (IRB) compliance and quality assurance audits; computer system validation and 21 CFR Part 11 compliance; LIMS/data management system compliance; and 21 CFR, GCP, cGMP, and ICH compliance. Stone is the author of Bubble Gum Badge—An FDA His-Story (Xlibris Corp., 2011). You can follow Stone on Twitter.